Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (1)
  • Open Access


    Use of the Naphthoquinone YM155 (Sepantronium Bromide) in the Treatment of Cancer: A Systematic Review and Meta-Synthesis

    Dariimaa Ganbat1,2, Bat-Erdene Jugder3, Lkhamaa Ganbat4, Miki Tomoeda5, Erdenetsogt Dungubat2,6, Ambaga Miyegombo7, Gantsetseg Garmaa8, Yoshihisa Takahashi6, Ryuji Fukuzawa6, Ichiro Mori6, Takayuki Shiomi6, Akinori Nakata9, Yasuhiko Tomita6,*

    Oncologie, Vol.24, No.2, pp. 195-225, 2022, DOI:10.32604/oncologie.2022.022299

    Abstract Most cancer cells overexpress the anti-apoptotic protein survivin and display redox dysregulation originating from genotypic and phenotypic alterations. These disturbances contribute to the uncontrolled proliferation, invasion, and chemoresistance of cancer cells, yet they also represent a specific vulnerability that could be exploited therapeutically in selected tumors. YM155 (sepantronium bromide) is a naphthoquinone-containing imidazolebased compound that selectively inhibits survivin expression at the transcriptional and post-transcriptional levels. Here, we performed a systematic review and meta-analysis of clinical studies in which YM155 was administered as monotherapy or combination therapy for patients with cancer. We assessed fully or partially reported clinical outcomes and pharmacological… More >

Displaying 1-10 on page 1 of 1. Per Page  

Share Link